Improving survival further by adding new drugs to R-CHOP has proven challenging, and prior to the introduction of Ritixumab the 7-drug ‘ProMACE-CytaBOM’ regimen failed to improve DLBCL survival relative to CHOP (Fisher et al., 1993). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.